Synthetic CAR-T Cells for Treating IL13Ra2 Positive Human and Canine Tumors

The EPO published patent application EP4021464A1 covering synthetic CAR-T cell compositions and methods for treating IL13Ra2 positive tumors in human and canine subjects. The application includes claims across multiple IPC classifications including A61K (pharmaceutical preparations), C12N (biotechnology), and C07K (proteins/peptides).

For pharmaceutical and biotechnology companies, this patent represents a potential freedom-to-operate consideration for CAR-T therapies targeting IL13Ra2. Universities and research institutions should assess whether this IP landscape affects their oncology immunotherapy programs. The designated states cover major European markets (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR).